Super-Low-Rate Pulsed Fluoroscopy Tied to Reduced Radiation Dose in ERCP for Bile Duct Stone Removal
Reducing fluoroscopy pulse rate to 1.0 pulse per second during endoscopic stone removal may lower radiation exposure with no difference in procedural success rate compared with standard rate.
Press Trust of India on MSN
Endoscopic surgery brings relief to patient suffering from chronic migraine
New Delhi, Oct 26 (PTI) A patient suffering from chronic migraine for nearly a decade has reported improvement in symptoms after undergoing endoscopic migraine surgery at a Delhi hospital, doctors sai ...
Mirror Now on MSN
AIG Hospitals and Boston Scientific partner to launch GI training centre in Hyderabad
AIG Hospitals and Boston Scientific have signed a three-year agreement to establish a Centre of Excellence in Hyderabad, focusing on advanced endoscopic training for doctors across India’s smaller ...
After trying diets and GLP-1 medications without lasting weight loss, former competitive weightlifter Dana Bichler lost more ...
The training will extend beyond doctors to include endoscopy technicians and nursing professionals, recognising the ...
THIS is with reference to the report `Lack of kidney stone removal procedure at hospitals adds to patients woes` (Sept 18), ...
A multimodal transformer-based AI framework achieved an AUC of 0.727 on preoperative endoscopic biopsy slides for predicting ...
Surgeons explore Uniportal and Biportal endoscopic spine techniques, hands-on training, and latest minimally invasive advancements at Thanjavur workshop.
A retrospective cohort study of 12,374 hospital patients in Japan found that adherence to a nurse-led dysphagia screening ...
In the SANO trial, active surveillance matched immediate surgery in terms of 5-year overall survival, but at the cost of more distant metastases and deaths from the cancer itself.
Stryker Corporation remains a global leader in medical technologies, with strong segment breadth and robust product ...
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results